DOI,title,author,year,times_seen
10.1016/j.coph.2017.09.010,Clinical pharmacokineticâ€“pharmacodynamic analyses: a critical element for developing antibacterial agents,Bhavnani,2017,1
10.1001/jama.282.13.1240,Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza,Hayden,2003,1
10.1086/420739,Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis,Ambrose,2004,1
10.1097/ccm.0b013e3181961bff,Pharmacokinetic issues for antibiotics in the critically ill patient,Roberts,2009,1
10.1159/000180580,Prediction of Creatinine Clearance from Serum Creatinine,Cockcroft,2008,1
10.1016/j.coph.2017.10.014,Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs,Lakota,2017,1
10.3109/03602538409015066,Alternative Approaches to Estimation of Population Pharmacokinetic Parameters: Comparison with the Nonlinear Mixed-Effect Model,Steimer,2007,1
